Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib [0.03%]
DNA修复抑制剂rucaparib增强结直肠癌对伊立替康治疗的敏感性
Titto Augustine,Radhashree Maitra,Jinghang Zhang et al.
Titto Augustine et al.
Intended to explore synthetic lethality and develop better combinatorial regimens, we screened colorectal cancer (CRC) cells using poly ADP-ribose (PAR) polymerase (PARP) inhibitors and cytotoxic agents. We studied four PARP inhibitors and ...
Significant differences on submission lag following regulation reform for registration of novel therapeutic drugs in Taiwan [0.03%]
台湾新药注册法规改革后申请滞后的重要差异
I-Chen Sun
I-Chen Sun
Drug lag, which delays patients' access to medicinal products, is typically associated with pharmaceutical regulations. To shorten drug lag, health authorities may establish new policies to liberalize the regulations, a step that is importa...
Fenghai Zhou,Fa Zhang,Chuan Zhou et al.
Fenghai Zhou et al.
The human embryonic lethal abnormal visual protein, HuR, belongs to the Hu family of RNA-binding proteins. Over the past two decades, HuR has been extensively associated with multiple biological characteristics of tumors, including tumor de...
Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice [0.03%]
放射性核素188Re-抗表皮生长因子受体单克隆抗体（西妥昔单抗）的生物分布、药代动力学及其放免治疗效应研究
Ya-Jen Chang,Chung-Li Ho,Kai-Hung Cheng et al.
Ya-Jen Chang et al.
Background Cetuximab is a fully humanized IgG1 subclass monoclonal that binds specifically to the human epidermal growth factor receptor (EGFR). Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many huma...
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study [0.03%]
一项II期临床研究：在绝经后且体重超标的激素受体阳性、HER2阴性转移性乳腺癌患者中，二甲双胍与依维莫司和阿那曲唑联用的疗效及安全性
Clinton Yam,Francisco J Esteva,Miral M Patel et al.
Clinton Yam et al.
Background Increased adiposity is thought to result in worse clinical outcomes in patients with breast cancer through increased estrogen production, hyperinsulinemia, insulin resistance, and activation of the phosphatidylinositol-3-kinase/A...
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):345-351. DOI:10.1007/s10637-018-0700-z 2019
Screening, identification of prostate cancer urinary biomarkers and verification of important spots [0.03%]
前列腺癌尿液标志物的筛选、鉴定及重要斑点验证
Huijun Zhao,Xuhong Zhao,Ting Lei et al.
Huijun Zhao et al.
Prostate-specific antigen (PSA) has been widely used as the unique serum biomarker for the diagnosis of prostate cancer (PCa). When PSA is moderately increased (e.g., 4-10 ng/ml), it is difficult to differentiate benign prostatic hyperplasi...
MiR-181a, a new regulator of TGF-β signaling, can promote cell migration and proliferation in gastric cancer [0.03%]
miR-181a通过调节TGF-β信号促进胃癌细胞增殖和迁移的新机制研究
Shaohua Ge,Haiyang Zhang,Ting Deng et al.
Shaohua Ge et al.
Transforming growth factor-beta (TGF-β) signaling pathway plays pivotal roles in various types of cancer. TGF-β receptor 2 (TGFβR2) contains a kinase domain that phosphorylates and activates the downstream of the TGF-β signaling pathway...
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors [0.03%]
Tarextumab(Omp-59r5)治疗实体瘤Ⅰ期剂量递增和扩展研究
David C Smith,Rashmi Chugh,Amita Patnaik et al.
David C Smith et al.
Purpose This Phase I trial evaluated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel cross-reactive antibody which binds and selectively inhibits signaling vi...
Clinical Trial
Investigational new drugs. 2019 Aug;37(4):722-730. DOI:10.1007/s10637-018-0714-6 2019
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers [0.03%]
AB928在健康志愿者中的安全性和耐受性以及其作用机制的随机一期研究
Lisa Seitz,Lixia Jin,Manmohan Leleti et al.
Lisa Seitz et al.
Adenosine suppresses antitumor immune responses via A2a and A2b receptors expressed on intratumoral immune cells. This effect is mediated by increased cyclic adenosine 5'-monophosphate (AMP) levels and phosphorylation of cyclic AMP response...
Clinical Trial
Investigational new drugs. 2019 Aug;37(4):711-721. DOI:10.1007/s10637-018-0706-6 2019
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma [0.03%]
伏立诺他联合同期放化疗治疗局部晚期头颈部鳞状细胞癌I期临床试验
Theodoros N Teknos,J Grecula,A Agrawal et al.
Theodoros N Teknos et al.
Purpose Vorinostat is a potent HDAC inhibitor that sensitizes head and neck squamous cell carcinoma (HNSCC) to cytotoxic therapy while sparing normal epithelium. The primary objective of this Phase I study was to determine the maximally tol...
Clinical Trial
Investigational new drugs. 2019 Aug;37(4):702-710. DOI:10.1007/s10637-018-0696-4 2019